Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

Key Takeaways Vertex's Q3 EPS of $4.80 beat estimates, rising 10% year over year on$ 3.08B in revenues.Trikafta and Alyftrek fueled growth, while Casgevy sales fell 44% sequentially to $16.9M.VRTX tightened its total revenue guidance for 2025 from$ 11.85- $12 billion to$ 11.9 to $12.0 billion.Vertex Pharmaceuticals (VRTX) reported adjusted earnings of$ 4.80 per share for the third quarter of 2025, surpassing the Zacks Consensus Estimate of $4.55. Earnings rose around 10% year over year.Total revenues of$ 3.0 ...